Molecular Therapeutics

The goal of the Molecular Therapeutics Program is to foster the exchange of ideas, cooperation, and collaboration leading to translation of basic research into the clinic, and to use basic research to answer clinical questions related to improving strategies for the treatment of cancer.

Focus on Molecular Therapeutics

Study Evaluates Newer Treatment for Women Whose Breast Cancer Has Spread

Results from a phase III clinical trial comparing a newer chemotherapy agent called eribulin mesylate with capecitabine, a standard drug used for chemotherapy today in women with previously treated metastatic breast cancer, showed that eribulin demonstrated a trend toward improved overall survival.

Program Director:
Alan Eastman, PhD

The Program provides a forum for discussion of new developments in cellular and molecular biology, with particular focus on cell cycle regulation, signal transduction, apoptosis and differentiation, as well as development of potentially novel therapeutic strategies within these foci.

Molecular Therapeutics